Grants and Contributions:
Title:
COVID-19 Vaccine: Phase 3 Clinical Trial of DNA-Based Vaccine Booster Covigenix VAX-001-1c
Agreement Number:
1000363
Agreement Value:
$10,000,000.00
Agreement Date:
Sep 1, 2022 - Mar 31, 2024
Description:
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001-1c bivalent vaccine candidate through Phase 3 clinical trials to establish its safety and immunogenicity in healthy adults as a booster to approved vaccines.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T5J 4P6
Reference Number:
172-2022-2023-Q4-1000363
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
816561112
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.
Amendment Date
Dec 4, 2023
Recipient's Legal Name:
Entos Pharmaceuticals Inc.
Federal Riding Name:
Edmonton Centre
Federal Riding Number:
48014
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: